Testosterone replacement and prostate cancer

Ranjith Ramasamy, Erik S. Fisher, Peter N. Schlegel

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

This article is intended as a review of the available clinical data outlining the risks and benefits of testosterone (androgen) replacement therapy, specifically addressing the issue of the relationship between exogenous androgen administration and prostate cancer risk. There is controversy over whether androgen replacement is a risk factor for incident prostate cancer. Our review of current clinical information revealed that to date, no study or review has definitively shown that androgen replacement therapy is an independent risk factor for development of prostate cancer. Androgen administration seems to be beneficial in decreasing fatal cardiovascular events, body fat mass, and insulin resistance. Overall, the current clinical data seems to suggest that androgen replacement is an appropriate therapeutic option for men with symptomatic hypogonadism provided that patients continue to receive regular prostate screenings.

Original languageEnglish (US)
Pages (from-to)123-128
Number of pages6
JournalIndian Journal of Urology
Volume28
Issue number2
DOIs
StatePublished - Apr 2012
Externally publishedYes

Fingerprint

Androgens
Testosterone
Prostatic Neoplasms
Hypogonadism
Insulin Resistance
Adipose Tissue
Prostate
Therapeutics

Keywords

  • Androgen replacement
  • hypogonadism
  • prostate

ASJC Scopus subject areas

  • Urology

Cite this

Testosterone replacement and prostate cancer. / Ramasamy, Ranjith; Fisher, Erik S.; Schlegel, Peter N.

In: Indian Journal of Urology, Vol. 28, No. 2, 04.2012, p. 123-128.

Research output: Contribution to journalArticle

Ramasamy, Ranjith ; Fisher, Erik S. ; Schlegel, Peter N. / Testosterone replacement and prostate cancer. In: Indian Journal of Urology. 2012 ; Vol. 28, No. 2. pp. 123-128.
@article{617a9fe3de9a4629aaceea81d574c0f8,
title = "Testosterone replacement and prostate cancer",
abstract = "This article is intended as a review of the available clinical data outlining the risks and benefits of testosterone (androgen) replacement therapy, specifically addressing the issue of the relationship between exogenous androgen administration and prostate cancer risk. There is controversy over whether androgen replacement is a risk factor for incident prostate cancer. Our review of current clinical information revealed that to date, no study or review has definitively shown that androgen replacement therapy is an independent risk factor for development of prostate cancer. Androgen administration seems to be beneficial in decreasing fatal cardiovascular events, body fat mass, and insulin resistance. Overall, the current clinical data seems to suggest that androgen replacement is an appropriate therapeutic option for men with symptomatic hypogonadism provided that patients continue to receive regular prostate screenings.",
keywords = "Androgen replacement, hypogonadism, prostate",
author = "Ranjith Ramasamy and Fisher, {Erik S.} and Schlegel, {Peter N.}",
year = "2012",
month = "4",
doi = "10.4103/0970-1591.98449",
language = "English (US)",
volume = "28",
pages = "123--128",
journal = "Indian Journal of Urology",
issn = "0970-1591",
publisher = "Medknow Publications and Media Pvt. Ltd",
number = "2",

}

TY - JOUR

T1 - Testosterone replacement and prostate cancer

AU - Ramasamy, Ranjith

AU - Fisher, Erik S.

AU - Schlegel, Peter N.

PY - 2012/4

Y1 - 2012/4

N2 - This article is intended as a review of the available clinical data outlining the risks and benefits of testosterone (androgen) replacement therapy, specifically addressing the issue of the relationship between exogenous androgen administration and prostate cancer risk. There is controversy over whether androgen replacement is a risk factor for incident prostate cancer. Our review of current clinical information revealed that to date, no study or review has definitively shown that androgen replacement therapy is an independent risk factor for development of prostate cancer. Androgen administration seems to be beneficial in decreasing fatal cardiovascular events, body fat mass, and insulin resistance. Overall, the current clinical data seems to suggest that androgen replacement is an appropriate therapeutic option for men with symptomatic hypogonadism provided that patients continue to receive regular prostate screenings.

AB - This article is intended as a review of the available clinical data outlining the risks and benefits of testosterone (androgen) replacement therapy, specifically addressing the issue of the relationship between exogenous androgen administration and prostate cancer risk. There is controversy over whether androgen replacement is a risk factor for incident prostate cancer. Our review of current clinical information revealed that to date, no study or review has definitively shown that androgen replacement therapy is an independent risk factor for development of prostate cancer. Androgen administration seems to be beneficial in decreasing fatal cardiovascular events, body fat mass, and insulin resistance. Overall, the current clinical data seems to suggest that androgen replacement is an appropriate therapeutic option for men with symptomatic hypogonadism provided that patients continue to receive regular prostate screenings.

KW - Androgen replacement

KW - hypogonadism

KW - prostate

UR - http://www.scopus.com/inward/record.url?scp=84872222081&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872222081&partnerID=8YFLogxK

U2 - 10.4103/0970-1591.98449

DO - 10.4103/0970-1591.98449

M3 - Article

C2 - 22919126

AN - SCOPUS:84872222081

VL - 28

SP - 123

EP - 128

JO - Indian Journal of Urology

JF - Indian Journal of Urology

SN - 0970-1591

IS - 2

ER -